2325.HK

Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million

Retrieved on: 
星期五, 八月 12, 2022
People, City, Outline, Laboratory, Health, ICL, Precision medicine, Fourteenth Finance Commission, Hematology, Population, Social change, Growth, Policy, National Economic Protectionism Association, Infection, Hospital, Frost, Pharmacogenomics, Molecular biology, Hospital Insurance and Diagnostic Services Act, Government, Mass spectrometry, Republic, Neoplasm, Immunoassay, Marketing, Patient, COVID-19, Biotechnology, Awareness, CAGR, Lists of diseases, Pathology, Physician, Solution, PCR, Pharmaceutical industry, Medical imaging, Medical device, Group

Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.

Key Points: 
  • Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.
  • Diagnostic testing services for medical institution alliances mainly assists leading hospitals in establishing on-site diagnosis centers covering four main types (i.e.
  • Revenue from this segment rose by 166.2% to RMB650.7 million as at the Reporting Period.
  • As of 30 June 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million, compared with a full-year average revenue of RMB2.2 million in 2021.